Literature DB >> 23454765

Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Gerald Willimsky1, Karin Schmidt, Christoph Loddenkemper, Johanna Gellermann, Thomas Blankenstein.   

Abstract

T cell surveillance is often effective against virus-associated tumors because of their high immunogenicity. It is not clear why surveillance occasionally fails, particularly against hepatitis B virus- or hepatitis C virus-associated hepatocellular carcinoma (HCC). We established a transgenic murine model of virus-induced HCC by hepatocyte-specific adenovirus-induced activation of the oncogenic SV40 large T antigen (TAg). Adenovirus infection induced cytotoxic T lymphocytes (CTLs) targeted against the virus and TAg, leading to clearance of the infected cells. Despite the presence of functional, antigen-specific T cells, a few virus-infected cells escaped immune clearance and progressed to HCC. These cells expressed TAg at levels similar to HCC isolated from neonatal TAg-tolerant mice, suggesting that CTL clearance does not select for cells with low immunogenicity. Virus-infected mice revealed significantly greater T cell infiltration in early-stage HCC compared with that in late-stage HCC, demonstrating progressive local immune suppression through inefficient T cell infiltration. Programmed cell death protein-1 (PD-1) and its ligand PD-L1 were expressed in all TAg-specific CD8+ T cells and HCC, respectively, which contributed to local tumor-antigen-specific tolerance. Thus, we have developed a model of virus-induced HCC that may allow for a better understanding of human HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454765      PMCID: PMC3582129          DOI: 10.1172/JCI64742

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  63 in total

1.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection.

Authors:  Laura K Mackay; Linda Wakim; Catherine J van Vliet; Claerwen M Jones; Scott N Mueller; Oliver Bannard; Douglas T Fearon; William R Heath; Francis R Carbone
Journal:  J Immunol       Date:  2012-01-23       Impact factor: 5.422

3.  Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV.

Authors:  D K Wong; D D Dudley; P B Dohrenwend; G M Lauer; R T Chung; D L Thomas; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

5.  Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms.

Authors:  M I Kafrouni; G R Brown; D L Thiele
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

6.  Possible role of cytotoxic T cells in acute liver injury in hepatitis C virus cDNA transgenic mice mediated by Cre/loxP system.

Authors:  T Wakita; A Katsume; J Kato; C Taya; H Yonekawa; Y Kanegae; I Saito; Y Hayashi; M Koike; M Miyamoto; Y Hiasa; M Kohara
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

7.  Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Hang Li; Ke Wu; Kaixiong Tao; Libo Chen; Qichang Zheng; Xiaoming Lu; Jun Liu; Liang Shi; Chuanqiao Liu; Guobin Wang; Weiping Zou
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

8.  Expression of tumour-specific antigens underlies cancer immunoediting.

Authors:  Michel DuPage; Claire Mazumdar; Leah M Schmidt; Ann F Cheung; Tyler Jacks
Journal:  Nature       Date:  2012-02-08       Impact factor: 49.962

9.  Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.

Authors:  Uciane K Scarlett; Melanie R Rutkowski; Adam M Rauwerdink; Jennifer Fields; Ximena Escovar-Fadul; Jason Baird; Juan R Cubillos-Ruiz; Ana C Jacobs; Jorge L Gonzalez; John Weaver; Steven Fiering; Jose R Conejo-Garcia
Journal:  J Exp Med       Date:  2012-02-20       Impact factor: 14.307

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  22 in total

Review 1.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

Review 2.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

Review 3.  Immunological landscape and immunotherapy of hepatocellular carcinoma.

Authors:  Jesús Prieto; Ignacio Melero; Bruno Sangro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

4.  Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma.

Authors:  Dong Liang; Huanzhou Xue; Yang Yu; Feng Lv; Wei You; Bin Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Authors:  Dai Liu; Guangfu Li; Diego M Avella; Eric T Kimchi; Jussuf T Kaifi; Mark P Rubinstein; E Ramsay Camp; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

6.  Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination.

Authors:  Annkristin Heine; Chrystel Flores; Heidrun Gevensleben; Linda Diehl; Mathias Heikenwalder; Marc Ringelhan; Klaus-Peter Janssen; Ulrich Nitsche; Natalio Garbi; Peter Brossart; Percy A Knolle; Christian Kurts; Bastian Höchst
Journal:  Oncoimmunology       Date:  2017-06-16       Impact factor: 8.110

Review 7.  Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Tai Hato; Andrew X Zhu; Dan G Duda
Journal:  Immunotherapy       Date:  2016-02-11       Impact factor: 4.196

Review 8.  Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

Authors:  Andrea Schietinger; Philip D Greenberg
Journal:  Trends Immunol       Date:  2013-11-06       Impact factor: 16.687

9.  Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.

Authors:  Guangfu Li; Dai Liu; Timothy K Cooper; Eric T Kimchi; Xiaoqiang Qi; Diego M Avella; Ningfei Li; Qing X Yang; Mark Kester; C Bart Rountree; Jussuf T Kaifi; David J Cole; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  J Hepatol       Date:  2016-08-09       Impact factor: 25.083

Review 10.  Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.

Authors:  Tai Hato; Lipika Goyal; Tim F Greten; Dan G Duda; Andrew X Zhu
Journal:  Hepatology       Date:  2014-09-26       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.